K
Kiniksa Pharmaceuticals Ltd D
D
KNSA
21.860
USD
0.57
(2.68%)
Market Open
Volume
5,456
EPS
0
Div Yield
-
P/E
-182
Market Cap
1,578,326,211
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Kiniksa Pharmaceuticals International plc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.